AIXCHIGH SIGNALOPERATIONAL10-K

AIXC has undergone a complete business transformation from an early-clinical-stage therapeutics company to a technology infrastructure company focused on AI and blockchain systems.

This represents a fundamental pivot away from drug development toward emerging technology infrastructure, which dramatically alters the company's risk profile, market opportunity, and investor base. The shift from biotech to AI/blockchain infrastructure suggests management believes greater value creation lies in programmable systems and asset tokenization rather than pharmaceutical development.

Comparing 2026-03-30 vs 2025-06-30View on EDGAR →
FINANCIAL ANALYSIS

The financial results show a company in transition with revenue declining modestly to $5.0M while R&D expenses were substantially reduced to $185K, reflecting the move away from clinical-stage drug development. Current liabilities increased meaningfully to $3.3M while total liabilities decreased significantly to $4.1M, suggesting a restructuring of the balance sheet during this business transformation. The overall picture indicates a company reallocating resources from pharmaceutical R&D toward its new technology infrastructure focus.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-84.6%
$1.2M→$185K

R&D spending cut 84.6% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+65.8%
$2.0M→$3.3M

Current liabilities surged 65.8% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
-59.9%
$10.3M→$4.1M

Liabilities reduced 59.9% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
+50.2%
$1.1M→$1.6M

Inventory surged 50.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Accounts Receivable
Balance Sheet
-34.5%
$822K→$539K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
+22.5%
$134K→$165K

Capex increased 22.5% — ongoing investment in capacity or infrastructure for future growth.

Revenue
P&L
-11.9%
$5.7M→$5.0M

Revenue softened 11.9% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-06-30
ADDED
As of March 23, 2026, the Registrant had 20,234,993 shares of Common Stock issued and outstanding.
(the Company ) that involve risks and uncertainties and reflect our judgment as of the date of this Annual Report.
(Nasdaq: AIXC) ( AIxC, we, us, or the Company ) is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems.
The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets ( RWA ) and the deployment of Embodied Artificial Intelligence ( EAI ) in commercial environments.
Our mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.
We believe that two structural shifts are reshaping global capital markets and physical infrastructure simultaneously: the migration of asset ownership and transaction finalization to distributed ledger technology, and the proliferation of AI-enabled physical systems such as autonomous vehicles, robotics, and connected systems that generate, consume, and require programmable infrastructure.
AIxC is purpose-built to sit at the intersection of these trends.
Strategic Realignment In September 2025, the Company closed a $41 million PIPE financing and subsequently , in November 2025, rebranded from Qualigen Therapeutics to AIxCrypto Holdings, Inc.
Following the transaction, the Company operated across three business lines under its Three Driving Forces framework: the BesTrade DeAI Agent platform, the C10 digital asset treasury and portfolio management tools, and the RWA Embodied AI (EAI) ecosystem.
In February 2026, the Company s board determined to concentrate on the RWA + Embodied AI (EAI) ecosystem.
REMOVED
As of June 26, 2025, the Registrant had 1,635,475 shares of common stock, par value $ 0.001 per share, issued and outstanding.
that involve risks and uncertainties and reflect our judgment as of the date of this Annual Report.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated.
BUSINESS Overview We are an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer.
Our business now consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS).
In addition, on April 11, 2024, we entered into a Co-Development Agreement (the Co-Development Agreement ) with Marizyme, Inc.
The Exclusivity Period has ended, and we do not intend to expand the Exclusivity Period.
Our lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer).
Such binding could, by stabilizing the G4s against DNA unwinding, help inhibit cancer cell proliferation.
QN-302 is currently undergoing a Phase 1a clinical trial at START Midwest in Grand Rapids, Michigan, and HonorHealth in Scottsdale, Arizona.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →